No Data
No Data
No Data
No Data
No Data
Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects
TipRanksApr 11 11:15 ET
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,
GlobeNewswireApr 9 16:05 ET
Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership
TipRanksApr 2 06:46 ET
Express News | Cantor Fitzgerald Reiterates Overweight on SCYNEXIS
Moomoo 24/7Apr 1 08:31 ET
SCYNEXIS Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 — Cantor Fitzgerald Reiterates → Overweight 08/15/2023 893.38% Cantor Fitzgerald → $15 Reitera
BenzingaApr 1 08:30 ET
SCYNEXIS Q4 EPS $(0.39) Misses $(0.20) Estimate, Sales $5.80M Beat $1.37M Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.20) by 95 percent. This is a 30 percent decrease over losses of $(0.30) per sha
BenzingaMar 28 23:36 ET
No Data
No Data